Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma

Background:Renal cell carcinoma (RCC) is highly resistant to chemotherapy because of a high apoptotic threshold. Recent evidences suggest that GSK-3β positively regulates human pancreatic cancer and leukaemia cell survival in part through regulation of nuclear factor (NF-κB)-mediated expression of anti-apoptotic molecules. Our objectives were to determine the expression pattern of GSK-3β and to assess the anti-cancer effect of GSK-3β inhibition in RCC.Methods:Immunohistochemistry and nuclear/cytosolic fractionation were performed to determine the expression pattern of GSK-3β in human RCCs. We used small molecule inhibitor, RNA interference, western blotting, quantitative RT–PCR, BrDU incorporation and MTS assays to study the effect of GSK-3β inactivation on renal cancer cell proliferation and survival.Results:We detected aberrant nuclear accumulation of GSK-3β in RCC cell lines and in 68 out of 74 (91.89%) human RCCs. We found that pharmacological inhibition of GSK-3 led to a decrease in proliferation and survival of renal cancer cells. We observed that inhibition of GSK-3 results in decreased expression of NF-κB target genes Bcl-2 and XIAP and a subsequent increase in renal cancer cell apoptosis. Moreover, we show that GSK-3 inhibitor and Docetaxel synergistically suppress proliferation and survival of renal cancer cells.Conclusions:Our results show nuclear accumulation of GSK-3β as a new marker of human RCC, identify that GSK-3 positively regulates RCC cell survival and proliferation and suggest inhibition of GSK-3 as a new promising approach in the treatment of human renal cancer.

[1]  J. Salles,et al.  A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia , 2006, Oncogene.

[2]  Mark J. Murphy,et al.  Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy , 2008, Nature.

[3]  A. Baldwin,et al.  Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. , 2008, Cancer research.

[4]  V. Bilim,et al.  Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma , 2006, British Journal of Cancer.

[5]  R. Bukowski.  Cytokine therapy for metastatic renal cell carcinoma. , 2001, Seminars in urologic oncology.

[6]  M. Kattan,et al.  Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma , 2006, Annals of Surgical Oncology.

[7]  S. Pastorino,et al.  Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. , 2008, Cancer research.

[8]  C. Pérez,et al.  First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. , 2002, Journal of medicinal chemistry.

[9]  Xin Lu,et al.  Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. , 2006, Cell research.

[10]  R. Bukowski.  Natural history and therapy of metastatic renal cell carcinoma , 1997, Cancer.

[11]  R. Urrutia,et al.  Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. , 2005, Cancer research.

[12]  Masafumi Ohtsubo,et al.  Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells , 2001, Oncogene.

[13]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation , 2000, Nature.

[14]  Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of beta-catenin gene mutations. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Masafumi Ohtsubo,et al.  Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. , 2003, Carcinogenesis.

[16]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. , 2000, Nature.

[17]  J. Patard,et al.  Renal cell carcinoma guideline. , 2007, European urology.

[18]  R. Motzer,et al.  Targeted therapy for metastatic renal cell carcinoma , 2006, British Journal of Cancer.

[19]  J. Waxman,et al.  Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth , 2004, Oncogene.

[20]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.

[21]  M. Atkins,et al.  GSK-3β Inhibition Enhances Sorafenib-induced Apoptosis in Melanoma Cell Lines* , 2008, Journal of Biological Chemistry.

[22]  R. Urrutia,et al.  Glycogen Synthase Kinase-3β Participates in Nuclear Factor κB–Mediated Gene Transcription and Cell Survival in Pancreatic Cancer Cells , 2005 .

[23]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[24]  Bin Zhang,et al.  Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. , 2005, Biochemical and biophysical research communications.

[25]  V. Bilim,et al.  Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis , 2008, British Journal of Cancer.

[26]  Herb Chen,et al.  Inactivation of glycogen synthase kinase-3β, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells , 2007, Molecular Cancer Therapeutics.

[27]  R. Jope,et al.  Resolution of the Nuclear Localization Mechanism of Glycogen Synthase Kinase-3 , 2007, Journal of Biological Chemistry.

[28]  A. Baldwin,et al.  Glycogen Synthase Kinase 3β Functions To Specify Gene-Specific, NF-κB-Dependent Transcription , 2005, Molecular and Cellular Biology.

[29]  K. Magnússon,et al.  Frequent expression of Bcl‐2 in renal‐cell carcinomas carrying wild‐type p53 , 1996, International journal of cancer.

[30]  C. Bokemeyer,et al.  Chemotherapy for renal cell carcinoma. , 1999, Anticancer research.

[31]  Z. Hall.  Cancer , 1906, The Hospital.

[32]  T. Smyrk,et al.  Aberrant Nuclear Accumulation of Glycogen Synthase Kinase-3β in Human Pancreatic Cancer: Association with Kinase Activity and Tumor Dedifferentiation , 2006, Clinical Cancer Research.

[33]  Xin Lu,et al.  Glycogen synthase kinase-3β positively regulates the proliferation of human ovarian cancer cells , 2006, Cell Research.

[34]  J. Thrasher,et al.  Lithium suppresses cell proliferation by interrupting E2F–DNA interaction and subsequently reducing S–phase gene expression in prostate cancer , 2007, The Prostate.

[35]  J W Yates,et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.

[36]  Sven Hellberg,et al.  Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418* , 2003, Journal of Biological Chemistry.

[37]  M. Rettig,et al.  Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. , 2004, Molecular cancer therapeutics.